1st Quarter - Amendment

JENNINGS POLICY STRATEGIES for GENERIC PHARMACEUTICAL ASSOCIATION

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

LobbyistCovered position, as disclosed
KATHERINE HAYES HEALTH COUNSEL, US SENATOR EVAN BAYH
CHRISTOPHER JENNINGS —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Office of Management & Budget (OMB); SENATE; Congressional Budget Office (CBO)

Bills named: H.R. 1427 (111th), S. 726 (111th), H.R. 1548 (111th)

Medicare/Medicaid MMM

Average Manufacturers Price/AMP including H.R. 6331 Any matters relating to access to generic drugs

LobbyistCovered position, as disclosed
KATHERINE HAYES HEALTH COUNSEL, US SENATOR EVAN B AYH
CHRISTOPHER JENNINGS —

Contacted: SENATE; Office of Management & Budget (OMB); White House Office; HOUSE OF REPRESENTATIVES; Congressional Budget Office (CBO)

Bills named: H.R. 6331 (111th)

Pharmacy PHA

Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

LobbyistCovered position, as disclosed
KATHERINE HAYES HEALTH COUNSEL, US SENATOR EVAN BAYH
CHRISTOPHER JENNINGS —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Congressional Budget Office (CBO)

Bills named: H.R. 1548 (111th), S. 726 (111th), H.R. 1427 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.